Astec LifeSciences Limited, part of the Godrej Agrovet Group, is a leading manufacturer of agrochemicals and pharmaceutical intermediates in India. With a strong focus on research, innovation, and global exports, the company has established itself as a key player in the specialty chemicals sector.
In this article, we will explore Astec LifeSciences’ share price targets from 2025 to 2030, along with essential insights for investors.
Detail | Value |
---|---|
Current Price | ₹819.90 |
Previous Close | ₹819.35 |
Day's High | ₹920.00 |
Day's Low | ₹815.50 |
52-Week High | ₹1,333.50 |
52-Week Low | ₹634.60 |
Market Capitalization | ₹2,010 Cr |
Beta (Volatility) | 0.70 |
Book Value per Share | ₹212.00 |
Face Value | ₹10 |
All-Time High | ₹2,288.80 |
All-Time Low | ₹13.85 |
Founded in 1994 and later acquired by Godrej Agrovet, Astec LifeSciences Limited manufactures agrochemical active ingredients, intermediates, and formulations. The company serves both domestic and international markets, with a strong presence in the US, Europe, and Latin America.
Strong parentage under Godrej Group.
Diversified product portfolio in fungicides, herbicides, and pharmaceutical intermediates.
Export-driven growth with 60%+ revenue from overseas.
R&D focus for introducing high-margin specialty chemicals.
Conservative beta (0.70), suggesting lower volatility compared to peers.
Investor Type | Holding (%) |
---|---|
Promoters | 72.42% |
Retail & Others | 23.55% |
Mutual Funds | 4.01% |
Foreign Institutions | 0.02% |
This shareholding pattern indicates strong promoter confidence, with retail participation also being significant.
Year | Minimum Target (₹) | Maximum Target (₹) |
---|---|---|
2025 | 850 | 930 |
2026 | 970 | 1,080 |
2027 | 1,120 | 1,280 |
2028 | 1,300 | 1,520 |
2029 | 1,480 | 1,720 |
2030 | 1,700 | 2,000 |
These projections are based on market growth trends, financial performance, sector expansion, and global demand for agrochemicals.
Astec is expected to show steady performance in 2025, supported by stable demand for agrochemicals and cost optimization.
Why?
Strong monsoon-driven agriculture demand.
Increasing global exports.
Lower volatility due to low beta (0.70).
Investment Advice: Good time for staggered entry.
In 2026, the company could benefit from higher export realizations and new product launches.
Why?
Focus on high-value fungicides.
Strategic expansion in Europe.
Better margins from backward integration.
Investment Advice: Hold for long-term compounding returns.
The year 2027 may bring strong financial results, supported by innovation in R&D.
Why?
Introduction of niche agrochemical molecules.
Higher demand in October-November agriculture season.
Improved operating profit margins.
Investment Advice: Reinvest dividends; maintain portfolio weightage.
By 2028, Astec could witness strong earnings growth.
Why?
Sustainable agrochemical products gaining traction.
Strong balance sheet and increasing book value per share.
Growth in pharmaceutical intermediates.
Investment Advice: Continue investing for CAGR returns.
Exports and new markets may help Astec expand significantly in 2029.
Why?
Growing demand in Latin America.
Stable promoter holding.
Consistent growth in net profit.
Investment Advice: Ideal for long-term investors.
By 2030, Astec could become a major player in the global agrochemical segment.
Why?
Diversification across agrochemicals and pharma intermediates.
Strong R&D focus.
Rising agricultural demand globally.
Investment Advice: Excellent for wealth creation and portfolio diversification.
Yes. Astec LifeSciences shows strong fundamentals, promoter backing, and growing demand for agrochemicals, making it a good long-term bet.
Strong promoter holding (72.42%).
Diversified export-driven growth.
Consistent book value increase.
Low beta stock, less volatile compared to peers.
Dependency on agrochemical demand cycles.
Regulatory restrictions in key markets.
Commodity price volatility.
Astec LifeSciences Limited is a fundamentally strong company with robust promoter backing from the Godrej Group. With its presence in both domestic and global markets, strong R&D capabilities, and a healthy balance sheet, Astec offers promising opportunities for long-term investors.
Currently trading around ₹819.90, analysts believe the stock has potential to reach ₹2,000 by 2030. For investors seeking growth in the specialty chemicals and agrochemicals sector, Astec LifeSciences can be a solid portfolio choice.
1. What is the current share price of Astec LifeSciences?
The current share price is around ₹819.90 (August 2025).
2. What is the share price target for Astec LifeSciences in 2025?
The 2025 share price target is between ₹850 – ₹930.
3. Is Astec LifeSciences a good buy now?
Yes, given its promoter backing, low volatility, and export-driven growth, it’s considered a good long-term buy.
4. What is Astec LifeSciences’ all-time high and low?
All-time high: ₹2,288.80; All-time low: ₹13.85.
5. Should I invest in Astec LifeSciences for the long term?
Yes, especially if you’re looking for exposure in agrochemicals and specialty chemicals.
???? Disclaimer: This article is for educational purposes only. Please consult a certified financial advisor before investing.